Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 2, 1998, Pages 358-361

  Drusano, George L ^a   Stein, Daniel S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MATHEMATICAL MODEL; NONLINEAR SYSTEM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MODELS, BIOLOGICAL; MODELS, THEORETICAL; POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

EID: 0031916622     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cavert, W., K. Staskus, M. Zupanic, S. Wietgrefe, D. Notermans, S. Danner, K. Henry, R. Mills, and A. T. Haase. 1997. Quantitative in situ hybridization measurement of HIV-1 RNA clearance kinetics from lymphoid tissue cellular compartments during triple drug therapy, abstr. LB9. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
2. Cohen, O. J., G. Pantaleo, M. Holodniy, C. H. Fox, J. M. Orenstein, S. Schnittman, M. Niu, C. Graziosi, G. N. Pavlakis, J. Lalezari, J. A. Bartlett, R. T. Steigbigel, J. Cohn, R. Novak, D. McMahon, J. Bilello, and A. S. Fauci. 1996. Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J. Infect. Dis. 173:849-856.
3. Collier, A. C., S. Bozzette, R. W. Coombs, D. M. Causey, D. A. Schoenfeld, S. A. Spector, C. B. Petinelli, G. Daivies, D. D. Richman, J. M. Leedom, P. Kidd, and L. Corey. 1990. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323:1015-1021.
4. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, Calif.
5. De Jong, M. D., J. Veenstra, N. I. Stilianakis, R. Schuurman, J. M. A. Lange, R. J. DeBoer, and C. A. B. Boucher. 1996. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc. Natl. Acad. Sci. USA 93:5501-5506.
6. Fischl, M. A., C. B. Parker, C. Pettinelli, M. Wulfsohn, M. S. Hirsch, A. C. Collier, D. Antoniskis, M. Ho, D. D. Richman, E. Fuchs, T. C. Merigan, R. C. Reichman, J. Gold, N. Steigbigel, G. S. Leoung, S. Rasheed, A. Tsiatis, and the AIDS Clinical Trial Group. 1990. A randomized cotrolled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med 323:1008-1014.
7. Frost, S. D., and A. K. McLean. 1994. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 8:323-332.
8. Galetto-Lacour, A., S. Yerly, T. V. Perneger, C. Baumberger, B. Hirschel, L. Perrin, and the Swiss HIV Cohort Study Group. 1996. Prognostic value of viremia in patients with long standing human immunodeficiency virus infection. J. Infect. Dis. 173:1388-1393.
9. Haase, A. T., K. Henry, M. Zupancic, G. Sedgewick, R. A. Faust, H. Melroe, W. Cavert, K. Gebhard, K. Staskus, Z.-Q. Zhang, P. J. Dailey, H. H. Balfour, Jr., A. Erice, and A. S. Perelson. 1996. Quantitative analysis of HIV-1 infection in lymphoid tissue. Science 274:985-989.
10. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
11. Mellors, J. W., C. K. Rinaldo, P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
12. Meng, T. C., M. A. Fischl, A. M. Boota, S. A. Spector, D. Bennett, Y. Bassiakos, S. Lai, B. Wright, and D. D. Richman. 1992. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. Ann. Intern. Med. 116:13-20.
13. Nordic Medical Research Councils' HIV Therapy Group. 1992. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Br. Med. J. 304:13-17.
14. O'Brien, W. A., P. M. Hartigan, D. Martin, J. Esenhart, A. Hill, S. Benoit, M. Rubin, M. S. Simberkoff, J. D. Hamilton, and the Veterans Affairs Cooperative Study Group on AIDS. 1996. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N. Engl. J. Med. 334:426-431.
15. Rocci, M. L., Jr., and W. J. Jusko. 1983. LAGRAN program for area and moments in pharmacokinetic analysis. Computer Programs in Biomedicine 16:203-216.
16. Stein, D., G. Drusano, R. Steigbigel, P. Berry, J. Mellors, D. McMahon, H. Teppler, C. Hildebrand, M. Nessly, and J. Chodakewitz. Two year followup of patients treated with indinavir 800 mg q8h, abstr. 195. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.
17. Stein, D. S., and G. L. Drusano. 1997. Modeling of the change in CD4 lymphocyte cell counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrob. Agents Chemother. 41:449-453.
18. Stein, D. S., D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau, and G. L. Drusano. 1996. A 24 week open label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10:485-492.
19. Stein, D. S., J. A. Korvick, and S. H. Vermund. 1992. CD4 lymphocyte cell enumeration for prediction of clinical course of HIV disease: a review. J. Infect. Dis. 165:352-363
20. Volberding, P. A., S. W. Lagakos, M. A. Koch, C. Pettinelli, M. W. Myers, D. K. Booth, H. H. Balfour, Jr., R. C. Reichman, J. A. Bartlett, M. S. Hirsch, R. L. Murphy, W. D. Hardy, R. Soeiro, M. A. Fischl, J. G. Bartlett, T. C. Merigan, N. E. Hyslop, D. D. Richman, F. T. Valentine, L. Corey, and the AIDS Clinical Trials Group of the National Institutes of Health. 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. N. Engl. J. Med. 322:941-949.
21. Wei, X., S. K. Ghosh, M. E. Taylor, et al. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
22. Wong, J. K., H. F. Gunthard, D. V. Havlir, et al. 1997. Reduction of HIV in blood and lymph nodes after potent antiretroviral therapy, abstr. LB10. In Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, D.C.